Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

12 Sökresultat.
Relevans Bedömning Nya först Gamla först

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 8 - Vital Signs; Local Laboratory - Haematology, Clinical Chemistry, Liver Events Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Biomarker Samples

- 17-05-19 - 1 Formulär, 9 Item-grupper, 158 Dataelement, 1 Språk
Item-grupper: Date of visit/ assessment, Vital Signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Liver Assessment, Investigatoinal Product Compliance - Pazopanib , Biomarker Sample
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 4 - Vital Signs; 12-Lead- ECG; Local Laboratory - Haematology, Clinical Chemistry, Liver Assessment; Urinalysis; Urinalysis - Local: 24h Protein Details; Investigational Product Compliance - Pazopanib; Biomarker Samples

- 17-05-19 - 1 Formulär, 10 Item-grupper, 164 Dataelement, 1 Språk
Item-grupper: Date of visit/ assessment, Vital Signs, 12-Lead ECG, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Local Laboratory - Urinalysis, Urinalysis - Local: 24 hour Protein Details, Liver Assessment, Investigatoinal Product Compliance - Pazopanib , Biomarker Sample
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Week 1 - Vital Signs; 12-Lead- ECG; Local Laboratory - Haematology, Clinical Chemistry; Investigational Product Compliance - Pazopanib; Liver Events Assessment; Biomarker Samples

- 16-05-19 - 1 Formulär, 8 Item-grupper, 149 Dataelement, 1 Språk
Item-grupper: Date of visit/ assessment, Vital Signs, 12-Lead ECG, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Investigational Product Compliance - Pazopanib, Liver Events Assessment, Biomarker Sample
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Oral GW786034 treatment for ovarian cancer NCT00281632 - Visit description: Treatment Period 3. Day 1

- 15-05-18 - 1 Formulär, 15 Item-grupper, 64 Dataelement, 1 Språk
Item-grupper: Header, Vital signs, ECOG Performance Status, Electronically transferred lab data - CA-125, Physical examination, Concomitant Medication, Adverse Events, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Urinalysis, Pharmacokinetics Blood, Investigational Product, Biomarker sample(s), investigational product, Treatment Confirmation
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Oral GW786034 treatment for ovarian cancer NCT00281632 - Visit description: Treatment Period 2. Day 1

- 15-05-18 - 1 Formulär, 16 Item-grupper, 74 Dataelement, 1 Språk
Item-grupper: Header, Vital signs, ECOG Performance Status, Electronically transferred lab data - CA-125, Physical examination, Concomitant Medication, Adverse Events, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Urinalysis, Pharmacokinetics Blood, Investigational Product, Biomarker sample(s), investigational product, Investigational Product, Treatment Confirmation
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Oral GW786034 treatment for ovarian cancer NCT00281632 - Visit description: Treatment Period 1. Day 8

- 14-05-18 - 1 Formulär, 5 Item-grupper, 38 Dataelement, 1 Språk
Item-grupper: Header, Vital signs, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, investigational product
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Oral GW786034 treatment for ovarian cancer NCT00281632 - Visit description: Treatment Period 1. Day 1

- 04-05-18 - 1 Formulär, 15 Item-grupper, 68 Dataelement, 1 Språk
Item-grupper: Header, Vital signs, ECOG Performance Status, Electronically transferred lab data - CA-125, Physical examination, Concomitant Medication, Adverse Events, Local Laboratory - Haematology, Local Laboratory - Clinical Chemistry, Urinalysis, tumour tissue sample collection, consent for tumour genetic research, Withdrawal of consent, tumour sample destruction, Biomarker sample(s)
Study ID: 104450 Clinical Study ID: VEG104450 Study Title: This study is a non-randomized, open-label, multi-center Phase II study of GW786034 to evaluate the administration of oral GW786034 in subjects with ovarian cancer. Clinicaltrials.gov Identifier: NCT00281632 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib Trade Name: Votrient Study Indication: Neoplasms, Ovarian CRF Pages: 722-853

Exploratory Biomarker Research Week 38 Mepolizumab HES NCT00086658 - Exploratory Biomarker Research Week 38

- 15-07-17 - 1 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: Biomarker
Study part: Exploratory Biomarker Research Week 38 / Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Exploratory Biomarker Research Week 24 Mepolizumab HES NCT00086658 - Exploratory Biomarker Research Week 24

- 12-07-17 - 1 Formulär, 1 Item-grupp, 2 Dataelement, 1 Språk
Item-grupp: Biomarker
Study part: Exploratory Biomarker Research Week 24.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Exploratory Biomarker Research Week 16 Mepolizumab HES NCT00086658 - Exploratory Biomarker Research Week 16

- 12-07-17 - 1 Formulär, 1 Item-grupp, 2 Dataelement, 1 Språk
Item-grupp: Biomarker
Study part: Exploratory Biomarker Research Week 16.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Exploratory Biomarker Research Week 12 Mepolizumab HES NCT00086658 - Exploratory Biomarker Research Week 12

- 10-07-17 - 1 Formulär, 1 Item-grupp, 3 Dataelement, 1 Språk
Item-grupp: Biomarker
Study part: Exploratory Biomarker Research Week 12.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Exploratory Biomarker Research Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Exploratory Biomarker Research Day 1 Pre-Infusion

- 11-06-17 - 1 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: Biomarker
Study part: Exploratory Biomarker Research Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial